Find comprehensive information on Chemotherapy-Induced Nausea and Vomiting (CINV), also known as Post-chemotherapy nausea and vomiting. This resource offers guidance on clinical documentation, medical coding, and healthcare best practices for managing CINV. Learn about diagnosis, treatment, and supportive care for patients undergoing chemotherapy. Improve your understanding of CINV and its impact on patient care with relevant medical terms and information for healthcare professionals.
Also known as
Nausea and vomiting
Nausea and vomiting due to chemotherapy.
Adverse effect of antineoplastic and immunosuppressive drugs
Adverse effect of chemotherapy, includes nausea and vomiting.
Encounter for antineoplastic chemotherapy
Encounter for chemotherapy, which can cause nausea and vomiting.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is nausea/vomiting related to chemotherapy?
Yes
Is it acute (<24 hours)?
No
Do NOT code as CINV. Find alternative diagnosis.
When to use each related code
| Description |
|---|
| Nausea and vomiting caused by chemotherapy |
| Nausea and vomiting NOT related to chemotherapy |
| Anticipatory nausea/vomiting before chemotherapy |
Coding CINV without specifying if it's acute, delayed, or breakthrough can lead to inaccurate reimbursement and quality reporting.
Failing to code the administration of antiemetics for CINV prophylaxis can result in lost revenue and underreporting of care provided.
Incorrectly coding the severity of CINV (mild, moderate, severe) impacts clinical documentation integrity and may trigger audits.
Q: What are the most effective antiemetic regimens for managing highly emetogenic chemotherapy-induced nausea and vomiting (CINV) in adult oncology patients?
A: Highly emetogenic chemotherapy (HEC) requires a multimodal antiemetic approach to effectively manage CINV. Current guidelines, such as those from the National Comprehensive Cancer Network (NCCN), recommend a combination of three or four antiemetic agents from different classes. This typically includes a neurokinin-1 receptor antagonist (NK1-RA) like aprepitant or fosaprepitant, a 5-HT3 receptor antagonist like ondansetron or granisetron, a corticosteroid like dexamethasone, and potentially olanzapine, especially in patients receiving cisplatin-based regimens. The specific regimen should be tailored to the patient's individual risk factors, such as age, comorbidities, and the specific chemotherapy agent being administered. Consider implementing a risk-stratified approach to CINV management to optimize patient outcomes. Explore how different combinations of antiemetics can address both acute and delayed CINV phases for comprehensive control.
Q: How do I differentiate and manage breakthrough chemotherapy-induced nausea and vomiting (CINV) despite prophylactic antiemetics in my patients receiving moderately emetogenic chemotherapy?
A: Breakthrough CINV, despite prophylactic antiemetics, can be challenging to manage in patients receiving moderately emetogenic chemotherapy (MEC). It's crucial to first assess if the initial antiemetic regimen was appropriate for the patient's risk level and the specific chemotherapy agent. If the regimen was suboptimal, consider escalating to a more robust prophylactic approach, potentially incorporating agents from different classes. For actual breakthrough CINV, rescue antiemetics from a different class than the prophylactic regimen should be administered promptly. Options include olanzapine, promethazine, or metoclopramide. Non-pharmacological strategies, such as acupuncture or acupressure, can also be considered as adjunctive therapies. Learn more about integrating non-pharmacological interventions into your CINV management protocols. Explore the latest research on personalized antiemetic approaches based on patient-specific factors and pharmacogenomic considerations.
Patient presents with complaints consistent with chemotherapy-induced nausea and vomiting (CINV), also referred to as post-chemotherapy nausea and vomiting. Onset of symptoms correlated with recent chemotherapy regimen for [Document specific chemotherapy agent(s) and dosage]. Patient reports [Specify frequency and severity of nausea episodes: e.g., "mild nausea throughout the day" or "severe vomiting episodes occurring 2-3 times per day"]. Symptoms impact patient's ability to [Specify impact on daily activities: e.g., "maintain adequate oral intake," "tolerate medications," or "perform activities of daily living"]. Assessment reveals [Document physical exam findings: e.g., "dry mucous membranes," "signs of dehydration," or "abdominal tenderness"]. Differential diagnosis includes other causes of nausea and vomiting, such as gastroenteritis, medication side effects (other than chemotherapy), and bowel obstruction. Diagnosis of CINV is supported by the temporal relationship to chemotherapy administration and the patient's reported symptom profile. Plan includes antiemetic therapy with [Document specific antiemetic medications prescribed and dosage: e.g., "ondansetron 8 mg PO TID" or "aprepitant 125 mg PO on day 1 of chemotherapy, then 80 mg PO daily for 2 days"]. Patient education provided regarding medication management, dietary modifications for nausea management (e.g., small, frequent meals, bland foods), and importance of maintaining hydration. Follow-up scheduled to monitor symptom control and adjust treatment as needed. ICD-10 code R11.2 (nausea and vomiting) and appropriate Z51.- code for encounter for antineoplastic chemotherapy are considered. Evaluation for delayed CINV will be conducted at subsequent visits.